Thermo Fisher Scientific CYB561D2 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1-3 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Goat / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide sequence (VSNAYLYRKRIQP) corresponding to the C-terminus amino acids of CYB561D2 (aa 210-222). if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CYB561D2,uniProtId:O14569-1,ncbiNodeId:9606,antigenRange:210-222,antigenLength:222,antigenImageFileName:PA5-18098_CYB561D2_O14569-1_Goat.svg,antigenImageFileNamePDP:PA5-18098_CYB561D2_O14569-1_Goat_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Ammonium sulfate precipitation

Storage buffer

TBS, pH 7.3, with 0.5% BSA

Contains

0.02% sodium azide

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

RRID

AB_11004784

Product Specific Information

This antibody is predicted to react with bovine, canine, mouse and rat based on sequence homology.

This antibody is tested in Peptide ELISA: antibody detection limit dilution 16,000.

Target Information

CYB561D2 (Cytochrome b561 domain-containing protein 2), also known as putative tumor suppressor protein 101F6, is a 222 amino acid highly hydrophobic protein that contains six membrane spanning domains. Localized to endosomes and endoplasmic reticulum of the perinuclear region, CYB561D2 contains 2 heme-binding sites, through which it reduces ferric ions. CYB561D2 is ubiquitously expressed, with highest levels in lung, liver and kidney. Though expression of CYB561D2 is abundant in normal lung bronchial epithileal cells, CYB561D2 is absent in most lung cancers. The gene encoding CYB561D2 maps to human chromosome 3p21.3, a region that is prone to genetic alterations and is associated with frequent and early allele loss in many human cancers. Exogenous expression of CYB561D2 leads to the induction of caspase-independent apoptotic and autophagic pathways, resulting in the synergistic killing of tumor cells. This suggests an important role for CYB561D2 as a therapeutic intervention in cancer treatment.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.